Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.96 | N/A | +12.26% |
management commentary, guidance changes, and full analysis available with Pro.
| +12.26% |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism about the company's future. They emphasized the importance of their ongoing research and development efforts.
Management highlighted strong performance in key therapeutic areas.
They acknowledged ongoing challenges in the market but expressed confidence in their pipeline.
Amgen's earnings report shows a solid EPS beat, indicating better-than-expected profitability. However, the stock's slight decline of 0.58% suggests that investors may have been looking for more comprehensive guidance or revenue figures. The lack of revenue data and guidance could have contributed to the stock's downward movement, despite the positive EPS surprise.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERIPRISE FINL INC
Apr 22, 2013